Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Advantest | Datadog | Moderna | |
|---|---|---|---|
| Moat rating | wide A disclosed share that rose while margin expanded. The FY2025 Annual Securities Report and Business Report (84th term, filed 2026-06-26) lists as FY2025 progress: 'Further expanded our market share in the semiconductor tester (ATE) market (CY2024: 58%; CY2025: 65%)', earned on net sales of ¥1,128,610 million at an operating income to net sales ratio of 44.2%, 'an increase of 14.9 percentage points from the previous fiscal year'. The share is a company metric and the filing says so — 'the ratio of Advantest's semiconductor tester sales to the overall size of the semiconductor tester market', where 'The semiconductor tester market size is estimated independently by Advantest based on certain assumptions and available information'. The same filing names seven principal tester competitors (Teradyne, Inc., CCTech, Accotest, YC Corp., Cohu, Inc., UniTest Co., Ltd. and EXICON Ltd.), so this is a lead held against a named field rather than an empty one. | narrow The FY2025 10-K grounds real stickiness — a trailing-12-month dollar-based net retention rate of "about 120%" as of December 31, 2025 and "approximately 84% of our customers were using two or more products" out of approximately 32,700 customers — but the same filing caps it. It names IBM, Microsoft and SolarWinds (on-premise infrastructure monitoring), Cisco, New Relic and Dynatrace (APM), Cisco and Elastic (log management) and "native solutions from cloud providers such as Amazon Web Services, or AWS, Microsoft Azure, and Google Cloud Platform" as competitors, plus "home-grown and open-source technologies", and concedes "many of our competitors have greater financial, technical and other resources, greater brand recognition, larger sales forces and marketing budgets". It further discloses an AI-native cohort "which cohort includes our largest customer and represented approximately seven percentage points of our year-over-year revenue growth for the quarter ended December 31, 2025" whose members "have rapidly increased their usage of our product and then optimized or may in the future optimize their usage". Sticky but bounded: narrow, not wide. | narrow The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion. |
| Moat type | intangibles ip What management itself names as the source of the position is a proprietary platform. The July 29, 2026 Q1 FY2026 results briefing states: 'Our leading SoC Test platform, V93000, has been widely adopted across a broad range of customers in the increasingly complex AI semiconductor markets, where advanced packaging technologies including GPUs, ASICs, and CPUs are being adopted. It serves as a key foundation that underpins our competitive advantage.' The 84th-term report shows the spend behind it: R&D was approximately ¥71.4 billion in FY2024 and ¥78.1 billion in FY2025, 'The number of employees in its research and development division is approximately 30% of the Advantest workforce', and in the Test System Business Segment 'a large and ongoing investment in research and development is necessary in order to maintain market competitiveness'. Its stated IP mitigation is that 'Advantest strategically and proactively files patent applications during product development and prior to product shipment'. | switching costs The 10-K locates the durable hold in platform integration rather than protected IP. A single agent collects "metrics, traces, logs, and other data"; under "One Data Model" every ingested datum is "consistently tagged with metadata regardless of its type", so different data types can be "queried together, correlated, alerted on, and visualized in a common user interface"; more than 1,000 out-of-the-box integrations bind it to the customer's stack; and the attach ladder deepens (approximately 84% of customers on two or more products, 55% on four or more, 33% on six or more and 18% on eight or more as of December 31, 2025). Displacing Datadog means re-instrumenting an estate the filing describes as "frequently deployed across a customer's entire infrastructure, making it ubiquitous". | intangibles ip The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power." |
| Leadership | clear leader The 84th-term report discloses Advantest's tester-market share at 65% in CY2025, up from 58% in CY2024, and carries the same 65% among its disclosed management metrics against a target of '58% or more'; the filing defines it as Advantest's semiconductor tester sales over a market size 'estimated independently by Advantest based on certain assumptions and available information'. The July 29, 2026 briefing names the platform behind that share — V93000, 'widely adopted across a broad range of customers in the increasingly complex AI semiconductor markets'. Teradyne, Inc. heads the filing's list of principal tester competitors. | co leader The 10-K claims only that "We believe that we compete favorably with respect to the factors listed above" — never category leadership — and names a distinct credible rival set in each category it serves, while conceding many of those rivals have greater resources and brand recognition. It does claim one first: being "the first to combine the 'three pillars of observability' - metrics, traces, and logs - into a single end-to-end platform" with log management in 2018. That reads as the leading independent among several credible rivals, not a clear leader. | co leader The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date." |
| Pricing power | strong Q1 FY2026 gross profit was ¥255,553 million on net sales of ¥367,473 million, and the July 29, 2026 briefing states the resulting figure itself: 'Gross margin reached 69.5%', with 'an operating margin of 51.7%'. Management attributes that level to 'a favorable sales mix and limited inventory valuation losses amid the robust demand environment', not to price, and guides FY2026 full-year gross margin to 66–67% and operating margin to 49.4% after incorporating 'the impact of higher component costs, particularly for memory-related components'. FY2025 closed at a 44.2% operating margin, up 14.9 points year on year, on sales up 44.7%. | moderate Expansion is real but volume-driven rather than price-driven. The 10-K attributes the increase in trailing-12-month dollar-based net retention to about 120% (from "high-110%'s" a year earlier) to "increased usage growth from existing customers", and describes self-service expansion by "adding hosts or volumes of data monitored". The same filing warns that if customers "reduce their usage, fail to renew their subscriptions or renew on different terms", then "our revenue and dollar-based net retention may decline" — a usage-metered model hands the customer a dial that seat-based pricing does not. | weak Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries." |
| Summary | Advantest sells the test step that certifies silicon before it ships, and its position there is disclosed rather than inferred: its own tester-market-share metric moved from 58% in CY2024 to 65% in CY2025 (84th-term Annual Securities Report), against a market size the filing says Advantest estimates itself. The lead is concentrated in SoC test — the July 29, 2026 briefing calls V93000 'our leading SoC Test platform' and 'a key foundation that underpins our competitive advantage' — and the customer base runs straight into the AI chain: NVIDIA International, Inc. was ¥228,273 million, or 20.2%, of FY2025 consolidated net sales, having been below the filing's 10% disclosure threshold the prior year, with Taiwan Semiconductor Manufacturing Co., Ltd. at ¥124,922 million, or 11.1%. Economics moved with it: FY2025 operating margin was 44.2%, up 14.9 points, and Q1 FY2026 gross margin reached 69.5%, which management attributes to 'a favorable sales mix and limited inventory valuation losses amid the robust demand environment' rather than to price. The counterweights sit in the same documents. The 84th-term report's customer-trust risk factor warns that if Advantest fails to meet expectations on ramp-up and post-sales service, 'the maintenance or expansion of Advantest's market share may be constrained'; it names separate competitor sets in test handlers (Hon. Precision, CCTech, Cohu, TechWing) and device interfaces (TSE, ISC, BeLINK) where no share is disclosed at all; and the July 29, 2026 briefing guides FY2026 full-year gross margin down to 66–67% having 'incorporated the impact of higher component costs, particularly for memory-related components, mainly in the second half of the fiscal year'. | Datadog's advantage is consolidation, not exclusivity. Per the FY2025 10-K it runs a modular platform of "over 20 products" fed by one agent and one tagged data model, deployed across a customer's whole estate with more than 1,000 integrations — so each additional product adopted makes the estate costlier to unwind, which shows up as roughly 120% dollar-based net retention and a multi-product attach ladder that thickened at every rung during 2025. What holds the rating at narrow rather than wide is that the filing itself names hyperscaler-native monitoring and open-source tooling as direct substitutes in the same categories, and flags an AI-native cohort including its largest customer that can optimize usage down as quickly as it ramped up. | Moderna's 10-K rests its competitive case on the mRNA platform and the IP wrapped around it: the company states it believes its capabilities "across mRNA technology, drug discovery, development and manufacturing" differentiate it, and reports more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed abroad, 485 pending applications, and granted patents on Spikevax, mNEXSPIKE and mRESVIA projected to expire in 2041 (U.S.) and 2036 (Europe), plus trade secrets and manufacturing know-how it calls substantial. The filing is equally direct about the limits: the principal COVID rival's vaccine "is also based on mRNA technology"; a competitor's European Commission contract keeps Moderna out of many European COVID markets until year-end 2026; RSV sales are "minimal to date" behind Pfizer and GSK; and the risk factors warn that "the mRNA medicines field is growing rapidly, with increased competitive pressure from large and more established pharmaceutical companies." What is durable is science and plant rather than commercial position: Moderna bought and operates the Norwood (MTC) campus, completed a Marlborough site purpose-built for intismeran autogene that began shipping patient batches in September 2025, and runs UK, Canada and Australia facilities that were fully licensed in 2025, each government having entered a multi-year commitment to purchase mRNA products from the company. |
| Chain position | Back-end capital equipment: Advantest's testers certify devices after fabrication, and the 84th-term report's FY2025 major-customer table puts NVIDIA International, Inc. at 20.2% and Taiwan Semiconductor Manufacturing Co., Ltd. at 11.1% of consolidated net sales, with overseas sales 97.8% of the total. | A software layer above the cloud rather than a supplier into it: the 10-K describes the platform as "cloud agnostic", deployable across "public cloud, private cloud, on-premise, multi-cloud, and hybrid environments", and monetizes the AI build-out through LLM Observability, which traces LLM chains and correlates them with APM. | A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.42 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm bearish Editorial prior, not backtested. |